Generex Biotechnology Corp., which owns Worcester’s Antigen Express Inc., has received a $3 million cash infusion.
Investors purchased $3 million worth of the company’s common stock and have an opportunity to purchase up to an additional $3 million in the next 60 days.
The company, which was recently delisted from the Nasdaq stock exchange because its share price was trading below $1, said it will use the money for research, development and preclinical trials.
The company also announced that it is increasing the number of patients involved in a phase II clinical trial of its breast cancer treatment from 190 patients to 330 patients. The company is working with The Henry M. Jackson Foundation for the Advancement of Military Medicine, Inc. in Maryland on the trial.
